Indeed, after normalizing the tumor telomeric content for each sample to its paired normal as an internal control, we observed significantly less telomere shortening in TP53-mutant AML/MDS compared to CBF AMLs (p=1.7×10−5; Figure 6B). The gene discussed is TP53; the disease is neoplasm.